Firebrick Pharma Limited (AU:FRE) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Firebrick Pharma Limited has announced the filing and successful validation of their Marketing Authorisation Application in Europe for Nasodine, a nasal antiseptic spray. The application is currently under evaluation, with an initial decision expected by 19 December 2024. If approved, the company plans to partner with European entities for manufacturing, distribution, and marketing.
For further insights into AU:FRE stock, check out TipRanks’ Stock Analysis page.